RxDoctor Payments Data

Tzonko Milev, MD

Nephrology · Tupelo, MSNPI 1689644510

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,648 of the $4,158 with a category attached, or 87.7%. It is spread thinly across 23 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,259 and has fallen 95.4% since, to $58 in 2025.

$4,158in general payments, 2019–2025

Across 204 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$732
  • Otsuka America Pharmaceutical, Inc.$461
  • Akebia Therapeutics Inc$450
  • Amgen$433
  • Travere Therapeutics, Inc.$349
  • Vifor Pharma, Inc.$289
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$3659%
  • Food & beverage$3,64888%
  • Education$1453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,158 in reported general payments places this provider in the 75th percentile of 105 nephrology providers in Mississippi.

See all nephrology providers in Mississippi

Medicare billing

Part B allowed, 2024
$255,517
Medicare patients
510
Services billed
3,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AuryxiaFerric Citrate54$84,023
VelphoroSucroferric Oxyhydroxide28$54,376
LokelmaSodium Zirconium Cyclosilicate17$17,475
Sevelamer Carbonate103$11,481
Lanthanum Carbonate13$9,473
Guanfacine Hcl63$3,388
Calcium Acetate66$2,776
Cinacalcet Hcl16$539
Losartan Potassium57$485
Guanfacine Hcl ErGuanfacine Hcl14$330
Allopurinol15$236
Potassium Chloride29$235
Metoprolol Tartrate11$199
Irbesartan11$171
Carvedilol29$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$450$84,02354 claims
Fresenius USA Marketing, Inc.Velphoro$134$54,37628 claims
AstraZenecaLokelma$732$17,47517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 nephrology providers in Mississippi.

Other nephrology in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →